An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis

Neurological Sciences

Volumn 35, Issue 10, 2014, Pages 1591-1597

  Chen, Xueping ^a   Guo, Xiaoyan ^a   Huang, Rui ^a   Zheng, Zhenzhen ^a   Chen, Yongping ^a   Shang, Hui Fang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

ALS FRS R; Amyotrophic lateral sclerosis; Creatinine; Survival

Indexed keywords

CREATININE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; EXPLORATORY RESEARCH; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; SURVIVAL; UNDERWEIGHT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED;

AMYOTROPHIC LATERAL SCLEROSIS; ASIAN CONTINENTAL ANCESTRY GROUP; CREATININE; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED;

EID: 84907451997     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1807-4     Document Type: Article

References (32)

1. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, Nicholson G, Ravits J, Shaw PJ, Swash M, Talbot K, Traynor BJ, Van den Berg LH, Veldink JH, Vucic S, Kiernan MC (2013) Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 12(3):310-322. doi: 10.1016/S1474-4422(13)70036-X
2. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942-955. doi: 10.1016/S0140-6736(10)61156-7
3. Kataoka H, Kiriyama T, Kobayashi Y, Horikawa H, Ueno S (2013) Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged >/=70 years. Am J Neurodegener Dis 2(2):140-144
4. Aksoy D, Cevik B, Solmaz V, Kurt SG (2013) Clinical, demographic and prognostic features of sporadic amyotrophic lateral sclerosis in Northern Turkey. Int J Neurosci. doi: 10.3109/00207454.2013.823605
5. Factor-Litvak P, Al-Chalabi A, Ascherio A, Bradley W, Chio A, Garruto R, Hardiman O, Kamel F, Kasarskis E, McKee A, Nakano I, Nelson LM, Eisen A (2013) Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 14(Suppl 1):33-43. doi: 10.3109/21678421.2013.778565
6. Korner S, Kollewe K, Ilsemann J, Muller-Heine A, Dengler R, Krampfl K, Petri S (2013) Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol 20(4):647-654. doi: 10.1111/ene.12015
7. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10(5-6):310-323. doi: 10.3109/17482960802566824
8. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD (2012) Biochemical alterations associated with ALS. Amyotroph Lateral Scler 13(1):110-118. doi: 10.3109/17482968.2011.619197
9. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V (2005) Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 6(1):37-44. doi: 10.1080/14660820510027035 (V21L0T6048V2555N)
10. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y (2012) Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 51(12):1501-1508 (DN/JST.JSTAGE/internalmedicine/51.7465)
11. Ikeda K, Kawabe K, Iwasaki Y (2009) Do serum uric acid levels reflect oxidative stress in the progression of ALS? J Neurol Sci 287(1-2):294. doi: 10.1016/j.jns.2009.08.008 (S0022-510X(09)00764-310) (author reply 295)
12. Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, Logroscino G (2011) An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol 258(2):238-243. doi: 10.1007/s00415-010-5735-9
13. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD (2011) Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease study equation. Am Heart J 162(3):548-554. doi: 10.1016/j.ahj.2011.06.006
14. Wyss M, Kaddurah-Daouk R (2000) Creatine and creatinine metabolism. Physiol Rev 80(3):1107-1213
15. Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD, Mendell JR (2009) Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve 40(3):438-442. doi: 10.1002/mus.21420
16. Simons JP, Schols AM, Buurman WA, Wouters EF (1999) Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 97(2):215-223
17. Hashizume A, Katsuno M, Banno H, Suzuki K, Suga N, Mano T, Atsuta N, Oe H, Watanabe H, Tanaka F, Sobue G (2012) Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 135(Pt 9):2838-2848. doi: 10.1093/brain/aws170
18. Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, Heilberg IP (2008) Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 3(2):348-354. doi: 10.2215/CJN.02870707
19. Ascherio A, Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Rodriguez C, Thun MJ (2004) Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 160(10):977-984. doi: 10.1093/aje/kwh312
20. Nilsen J, Brinton RD (2004) Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord 3(4):297-313
21. Cocker J, Mason HJ, Warren ND, Cotton RJ (2011) Creatinine adjustment of biological monitoring results. Occup Med (Lond) 61(5):349-353. doi: 10.1093/occmed/kqr084
22. Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD (2013) Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011. Neurol Clin Pract 3(4):313-320. doi: 10.1212/CPJ.0b013e3182a1b8ab.CPJ200147
23. Reich-Slotky R, Andrews J, Cheng B, Buchsbaum R, Levy D, Kaufmann P, Thompson JL (2013) Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 14(3):212-216. doi: 10.3109/21678421.2013.770028
24. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM (2011) Body mass index, not dys lipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44(1):20-24. doi: 10.1002/mus.22114
25. Shimizu T, Nagaoka U, Nakayama Y, Kawata A, Kugimoto C, Kuroiwa Y, Kawai M, Shimohata T, Nishizawa M, Mihara B, Arahata H, Fujii N, Namba R, Ito H, Imai T, Nobukuni K, Kondo K, Ogino M, Nakajima T, Komori T (2012) Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler 13(4):363-366. doi: 10.3109/17482968.2012.678366
26. Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, Preux PM, Couratier P (2011) Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 82(6):628-634. doi: 10.1136/jnnp.2010.211474
27. Slowie LA, Paige MS, Antel JP (1983) Nutritional considerations in the management of patients with amyotrophic lateral sclerosis (ALS). J Am Diet Assoc 83(1):44-47
28. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5(3):347-350. doi: 10.1038/6568
29. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, Burke D (2004) A clinical trial of creatine in ALS. Neurology 63(9):1656-1661 (63/9/1656)
30. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, Wokke JH, Franssen H, van den Berg LH (2003) A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53(4):437-445. doi: 10.1002/ana.10554
31. Atassi N, Ratai EM, Greenblatt DJ, Pulley D, Zhao Y, Bombardier J, Wallace S, Eckenrode J, Cudkowicz M, Dibernardo A (2010) A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11(6):508-513. doi: 10.3109/17482961003797130
32. Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR (2013) Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol. doi: 10.1001/jamaneurol.2013.4646